Actively Recruiting
A Study of Hospital-at-Home for People Receiving Tarlatamab
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-03-27
70
Participants Needed
7
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to find out whether a Hospital-at-Home (HaH) program is a more efficient way to monitor people's health after receiving tarlatamab than monitoring in the hospital (inpatient).
CONDITIONS
Official Title
A Study of Hospital-at-Home for People Receiving Tarlatamab
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of extensive stage small cell lung carcinoma (ES-SCLC)
- Planned treatment with commercially available tarlatamab monotherapy as standard of care
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status less than 2
- Adequate organ and bone marrow function as shown by recent lab tests:
- Absolute neutrophil count (ANC) ≥ 1000 cells/μL without recent growth factor support
- Platelet count ≥ 50,000/μL without recent transfusion
- Hemoglobin ≥ 8.0 g/dL without recent transfusion
- Liver enzymes (ALT, AST) ≤ 3 times upper limit of normal (ULN)
- Serum bilirubin ≤ 1.5 times ULN (up to 2 times ULN if known Gilbert disease)
- Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min using CKD-EPI formula
- Willingness to give and sign informed consent
- Residence in an appropriate homebound setting within defined geographic area or lodging at MSK Residence or hotel
- Must be accompanied by a caregiver during enrollment in the HaH program
- Identified primary caregiver by patient
- Treating physician managing tarlatamab treatment plan
You will not qualify if you...
- Active infection prior to starting tarlatamab, including grade 3 or higher viral, bacterial, or fungal infection
- Baseline dementia or cognitive barriers
- Uncontrolled arrhythmias
- Caregiver deemed inappropriate by treating physician
- No exclusion criteria for treating physician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, United States, 07920
Actively Recruiting
2
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, United States, 07748
Actively Recruiting
3
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, United States, 07645
Actively Recruiting
4
Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)
Commack, New York, United States, 11725
Actively Recruiting
5
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, United States, 10604
Actively Recruiting
6
Memorial Sloan Kettering Cancer Center (All Protocol Activites)
New York, New York, United States, 10065
Actively Recruiting
7
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York, United States, 11553
Actively Recruiting
Research Team
R
Robert Daly, MD, MBA
CONTACT
M
Michael Offin, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here